Anti-Her-2/CD3 bispecific mRNA-LNP

HER2 (human epidermal growth factor receptor 2) is a member of the human epidermal growth factor receptor (ERBB) family and is encoded by the human ERBB2 gene. In contrast to other members of the ERBB family, HER2 does not directly bind ligands. HER2 is overexpressed in a range of tumors, including breast, gastric, lung and ovarian cancers. It can be activated by heterodimerization with another ERBB member or by homodimerization when HER2 concentrations are high, such as in cancer. Overexpression of this oncogene has been shown to be associated with the development and progression of certain aggressive types of breast cancer. Therefore, HER2 is an important target for cancer therapy.
This product is designed as a tool for the delivery and expression of anti-Her-2 scfv/CD3-mut Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-Her-2 scfv/CD3-mut Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The Her-2 scfv/CD3-mut Fc fusion protein is approximately 80 kD and consists of anti-HER2 scFv (single-chain variable fragment), CD3ζ signaling domain and mutant human Fc. The full-length amino acid sequence of this anti-Her-2 scfv/CD3-mut Fc fusion protein is available upon request.